All In Biotech

Drug Trial Radar · NCT06560138

A Trial of SHR-4602 Infusion in Patients With SHR-4602 in Subjects With HER2-expressing or HER2-mutated Locally Advanced or Metastatic Solid Tumors

An Open-label, Multi-center Phase I Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SHR-4602 in Subjects With HER2-expressing or HER2-mutated Locally Advanced or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jan 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Mar 1, 2025

Primary completion

Dec 14, 2025

Study completion Sep 12, 2026

Sponsor

Lead sponsor
Atridia Pty Ltd.Industry
Sponsor type
Industry
First posted
Aug 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SHR-4602 in subjects with HER2-expressing or HER2-mutated locally advanced or metastatic solid tumors.

Conditions

  • HER2-expressing or HER2-mutated Locally or Metastatic Solid Tumors

Interventions

  • SHR-4602Drug

    SHR-4602 will be administered through IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. the phase II dose (RP2D) of SHR-4602Time frame: From the time when the subjects sign the informed consent form to 45(±3) days after the last dose of SHR-4602, or the start of new anti-tumor treatment (whichever comes first).assessed for a maximum duration of up to 1 year

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Scientia Clinical Research Limited

    Randwick, New South Wales, Australia

  • Macquarie University

    Sydney, New South Wales, Australia

  • Icon Cancer Centre South Brisbane

    Brisbane, Queensland, Australia

  • Cancer Research SA

    Adelaide, South Australia, Australia

  • Peninsula & South Eastern Haematology and Oncology Group

    Frankston, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.